These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25491042)

  • 1. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
    Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
    J Oncol Pract; 2015 Jan; 11(1):47-54. PubMed ID: 25491042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
    Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
    Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.
    Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
    Support Care Cancer; 2014 Dec; 22(12):3275-85. PubMed ID: 25082364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
    Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
    Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
    Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
    Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
    Flanigan JA; Yasuda M; Chen CC; Li EC
    Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
    Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
    Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with febrile neutropenia in the US.
    Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
    Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
    Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
    Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
    Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
    Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.
    Weycker D; Chandler D; Barron R; Xu H; Wu H; Edelsberg J; Lyman GH
    J Oncol Pharm Pract; 2017 Jan; 23(1):33-42. PubMed ID: 26568602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.
    Pathak R; Giri S; Aryal MR; Karmacharya P; Bhatt VR; Martin MG
    Support Care Cancer; 2015 Mar; 23(3):615-7. PubMed ID: 25556610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The
    Aagaard T; Reekie J; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
    Int J Cancer; 2020 Jan; 146(2):321-328. PubMed ID: 30839100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.